Oncology

Latest News

Innovation vs Affordability: Cancer Care’s Cost Crisis and Access Gap

Innovation vs Affordability: Cancer Care’s Cost Crisis and Access Gap

By Cameron Santoro

August 21st 2025

RIsing costs for therapies and inequities in reimbursement for genomic testing have created financial barriers for patients, according to appearing experts in Detroit, Michigan, on July 10, 2025.

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com

Predictive Model Forecasts Advanced NSCLC Outcomes

By Jared Kaltwasser

August 14th 2025

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

August 23rd 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 23rd 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

February 26th 2024

What We’re Reading: Alabama IVF Ruling Impacts; Administrative Task Fees; Nursing Shortage Response

Patients with cancer express shock and anxiety over the recent ruling by the Alabama Supreme Court regarding frozen embryos; doctors are beginning to charge fees for administrative tasks; some universities are implementing accelerated nursing programs to help with the shortage.

Blue folder with Cancer diagnosis | vchalup - stock.adobe.com

February 22nd 2024

COVID-19 Pandemic's Disruption on Cancer Detection in the US

A nationwide analysis reveals a significant drop in cancer diagnoses, highlighting an urgent need for a catch-up in screening efforts.

Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)

February 16th 2024

Kiana Mehring Discusses the Future of Value-Based Oncology Care

Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute, shares her thoughts on future directions in value-based oncology care and research.

Breast cancer - Axel Kock - stock.adobe.com.jpeg

February 14th 2024

Breast Cancer Incidence Highest Among Young Black Women in the US

Researchers have identified a surge in breast cancer rates among young women and racial disparities across age groups.

February 14th 2024

How Real-World Evidence Can Spur Collaboration and Changes in Oncology

Zhaohui Su, PhD

Chandler Cortina, MD, MS, FSSO, FACS | Image Credit: Froedtert & Medical College of Wisconsin

February 9th 2024

Getting to Know Dr Chandler Cortina, Breast Surgical Oncologist

Chandler Cortina, MD, MS, FSSO, FACS, is assistant professor of surgery and breast surgical oncologist at Froedtert & the Medical College of Wisconsin. His current research focuses on breast cancer risk not only in general but also among transgender and gender-diverse populations.

Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.

February 7th 2024

COA's Dr Miriam Atkins: PBMs, HR 5526, and Marketplace Strategy

Maggie L. Shaw Pearl Steinzor

Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance, discusses the impact of pharmacy benefit managers (PBMs) on health care costs and offers potential ways to remedy certain CMS decisions that negatively affect oncologists and their patients.

Blood sample test with positive diagnosis of thrombosis risk in a coagulation test | angellodeco - stock.adobe.com

February 2nd 2024

Risk of Venous Thromboembolism Increases After Cancer Surgery, Study Finds

The increased risk is likely due to the underlying cancer disease and adjuvant treatments, researchers find.

Enhertu (trastuzumab deruxtecan) product packaging | AstraZeneca photo

January 30th 2024

Priority Review Granted for Trastuzumab Deruxtecan; Would Be First Tumor-Agnostic ADC

A tumor-agnostic approval would be a significant development in the advance of antibody-drug conjugates (ADCs), which are designed to deliver a potent, cancer-fighting payload into a tumor while sparing nearby tissues.

Dr Lucy Langer

January 28th 2024

Dr Lucy Langer: How UnitedHealthcare Is Enhancing Oncology Pathway Adherence and Promoting Equity

Hayden E. Klein

UnitedHealthcare's oncology payment mode initially involved a pay-for-performance program based on pathways adherence, and will be transitioning in 2024 to a broader system with graded quartiles to incentivize greater participation and pathway adherence.

Samyukta Mullangi, MD, MBA | Image credit: X

January 22nd 2024

Dr Samyukta Mullangi Talks Cost Reductions, Scalability of Thyme Care's Navigation Program

Hayden E. Klein

The Thyme Care virtual navigation program demonstrated a $594 reduction in total costs per member per month for navigated cancer patients compared with a control group, emphasizing the scalability of the independent virtual navigation model across various contracts, with opportunities to adapt to different populations and needs in the evolving landscape of value-based care arrangements.

January 16th 2024

First-Line Tiragolumab With Atezolizumab Plus Chemo Improves PFS, OS in Patients With ESCC

Treatment with both PD-1 and TIGIT immunotherapy alongside chemotherapy demonstrated improved progression-free (PFS) and overall survival (OS) compared with chemotherapy alone in patients with esophageal squamous cell carcinoma (ESCC).

Kirollos Hanna | Image credit: LinkedIn

January 15th 2024

Dr Kirollos Hanna Talks Chemotherapy Shortage Challenges and Solutions

Hayden E. Klein

Especially during shortages, Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy services at Minnesota Oncology, says practices should carve out areas where going to a different therapeutic approach isn't considered off-pathway.

Doctor stacking wooden blocks with health care icons | image credit: REDPIXEL - stock.adobe.com

January 14th 2024

Navigating the Biosimilar Frontier: Opportunities and Challenges in 2024

Biosimilars offer substantial promise for a new era of accessibility and affordability for patients and the broader health care industry, but better understanding of these products from payers and providers is necessary for biosimilars to reach their full potential in the US.

Pile of dollars and stethoscope | nata777_7 - stock.adobe.com

January 11th 2024

Substantial State Variations Identified in Health Insurance Coverage at Cancer Diagnosis

Health insurance coverage is a strong determinant of cancer care access and survival, and the observed variations are despite a significant increase in coverage under the Affordable Care Act.

Edward Arrowsmith, MD, MPH

January 10th 2024

How Tennessee Oncology Navigates Clinical Pathway Challenges and Advancements: Dr Edward Arrowsmith

Hayden E. Klein

Edward "Ted" Arrowsmith, MD, MPH, medical director for pathways at OneOncology and managing partner at Tennessee Oncology, talks about challenges and changes in clinical pathways and the importance of keeping them updated.

Cancer awareness ribbons | SewcreamStudio - stock.adobe.com

January 8th 2024

Cancer Detection Rates Dropped Due to COVID-19 Disruptions, Study Finds

Cancer incidence fell by 8.7% across all cancer sites during the first year of the pandemic, according to a new study.

Dr Margaret Liang on Mitigating Financial Toxicity for Patients With Cancer

January 6th 2024

Dr Margaret Liang on Mitigating Financial Toxicity for Patients With Cancer

Pearl Steinzor Rose McNulty

Margaret Liang, MD, MSHPM, gynecologic oncologist and health services researcher and director, Gynecologic Oncology Fellowship Program, Cedars-Sinai Cancer Center, discusses financial toxicity in cancer care and how institutions can help alleviate the financial burden for patients.

Dr Amy Laughlin on At-Home Cancer Care Costs, Advancements

January 3rd 2024

Dr Amy Laughlin on At-Home Cancer Care Costs, Advancements

Brooke McCormick

Amy Laughlin, MD, MSHP, of Orlando Health commented on at-home cancer care costs and shared her predictions on how at-home cancer care will evolve.

Dr Kathi Mooney

January 3rd 2024

Dr Kathi Mooney Discusses Improving Patients' Quality of Life Through Technology

Brooke McCormick

Kathi Mooney, PhD, RN, FAAN, of the University of Utah, discussed technologies she and her team developed to help improve the quality of life of patients with cancer and their families.

Highlights From ASCO 2023

January 3rd 2024

ICYMI: Highlights From ASCO 2023

The most-read content from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including the latest findings in ongoing clinical trials, a panel discussion on Medicare oncology payment models, and the importance of alignment between clinicians and payers on clinical pathways.

The top 5 Institute for Value-Based Medicine content of 2023

December 27th 2023

Top 5 Content From Institute for Value-Based Medicine® Events in 2023

Laura Joszt, MA

In 2023, there were 18 oncology and 7 population health Institute for Value-Based Medicine® events cohosted with organizations such as Optum, OneOncology, Vanderbilt Ingram Cancer Center, Duke Health, Cleveland Clinic, and Memorial Sloan Kettering Cancer Center.

The Top 5 Oncology Articles of 2023

December 22nd 2023

Top 5 Most-Read Oncology Articles of 2023

Our most-read oncology content of 2023 included meeting coverage, research on an algorithm using patient-reported outcomes to predict hospital visits, and the launch of an National Comprehensive Cancer Network pilot project aiming to measure health equity.

Global-vegefox.com-stock.adobe.com

December 21st 2023

New Study Reveals Global Disparities in Access to Multiple Myeloma Cell Therapies

Giuliana Grossi

“Unfortunately, limited access to these therapies worldwide appears to be a major challenge,” the researchers wrote.

Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center

December 18th 2023

Dr Tiago Biachi Discusses Precision Medicine Advancements in Solid Tumors

Tiago Biachi de Castria, MD, PhD, associate member in the Department of Gastrointestinal Oncology at Moffitt Cancer Center, discusses how precision medicine tools have aided oncologists in treating patients with solid tumors, while reducing overall toxicity.

Highlights ACCC 2023 Annual Meeting and Cancer Center Business Summit

December 15th 2023

ICYMI: Highlights From ACCC Spring 2023

Our most-read coverage from the Association of Community Cancer Centers (ACCC) 2023 Annual Meeting and Cancer Center Business Summit highlighted ongoing issues in oncology policy and practice.

FDA on Paper Texture | Image credit: Araki Illustrations - stock.adobe.com

December 15th 2023

FDA Approves Belzutifan for Advanced RCC After PD-1 or PD-L1 Inhibition and a VEGF-TKI

The approval of belzutifan, an oral hypoxia-inducible factor-2 alpha inhibitor, provides a new option for patients with advanced renal cell carcinoma (RCC) following treatment with a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).

Highlights From the 2023 Community Oncology Conference

December 12th 2023

ICYMI: Highlights From the 2023 Community Oncology Conference

Our top coverage from this year’s Community Oncology Conference, hosted by the Community Oncology Alliance, included discussions around alternative payment models, shifts in the community oncology landscape in recent decades, and the need for reform in several areas.

stethoscope on charts - amazing studio - stock.adobe.com

December 8th 2023

California Aims for Equity by Redefining Cancer Care

Giuliana Grossi

Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.

Quit Smoking - s@photo - stock.adobe.com

December 7th 2023

Research Reveals the Role of Structural Racism in Lung Cancer Risk

Giuliana Grossi

Spanning 22 studies, the analysis illuminated housing disparities, occupational hazards, unequal health care access, economic inequality, and discriminatory industry practices and how they collectively contribute to heightened lung cancer risks.

...

8 9 10 11 12 13 14 15 16

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions